Literature DB >> 20930209

Pirfenidone in idiopathic pulmonary fibrosis.

J Swigris, D Fairclough.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20930209      PMCID： PMC3697094          DOI： 10.1183/09031936.00071710

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  2 in total

1.  Idiopathic pulmonary fibrosis and pirfenidone.

Authors:  H R Collard
Journal:  Eur Respir J       Date:  2010-04       Impact factor: 16.671

2.  Pirfenidone in idiopathic pulmonary fibrosis.

Authors:  H Taniguchi; M Ebina; Y Kondoh; T Ogura; A Azuma; M Suga; Y Taguchi; H Takahashi; K Nakata; A Sato; M Takeuchi; G Raghu; S Kudoh; T Nukiwa
Journal:  Eur Respir J       Date:  2009-12-08       Impact factor: 16.671
  2 in total
  3 in total

1.  Pirfenidone treatment of idiopathic pulmonary fibrosis.

Authors:  Ye Gan; Erica L Herzog; Richard H Gomer
Journal:  Ther Clin Risk Manag       Date:  2011-02-08       Impact factor: 2.423

2.  Gradual increase of high mobility group protein b1 in the lungs after the onset of acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Masahito Ebina; Hiroyuki Taniguchi; Taku Miyasho; Shingo Yamada; Naoko Shibata; Hiromitsu Ohta; Shu Hisata; Shinya Ohkouchi; Tsutomu Tamada; Hidekazu Nishimura; Akitoshi Ishizaka; Ikuro Maruyama; Yoshinori Okada; Kondo Takashi; Toshihiro Nukiwa
Journal:  Pulm Med       Date:  2011-02-21

3.  Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment.

Authors:  Arata Azuma; Yoshio Taguchi; Takashi Ogura; Masahito Ebina; Hiroyuki Taniguchi; Yasuhiro Kondoh; Moritaka Suga; Hiroki Takahashi; Koichiro Nakata; Atsuhiko Sato; Shoji Kudoh; Toshihiro Nukiwa
Journal:  Respir Res       Date:  2011-10-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.